Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
EV/IC
Enterprise Value to IC
Enterprise Value to Invested Capital (EV/IC) ratio is a valuation multiple that measures the dollars in Enterprise Value for each dollar of capital invested by shareholders and lenders.
Market Cap | EV/IC | ||||
---|---|---|---|---|---|
ES |
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
4.7B EUR | 7 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 032 690.2 | |
US |
Eli Lilly and Co
NYSE:LLY
|
771.7B USD | 13.5 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.2T DKK | 15.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 326.4 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
365.4B USD | 2.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
333.6B USD | 3.7 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
192.7B GBP | 32.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
185.7B CHF | 2.7 | ||
CH |
Novartis AG
SIX:NOVN
|
181.7B CHF | 2.6 | ||
US |
Pfizer Inc
NYSE:PFE
|
164.2B USD | 1.1 |
EV/IC Forward Multiples
Forward EV/IC multiple is a version of the EV/IC ratio that uses forecasted invested capital for the EV/IC calculation. 1-Year, 2-Years, and 3-Years forwards use invested capital forecasts for 1, 2, and 3 years ahead, respectively.